Propantheline bromide Rx
Generic Name and Formulations:
Propantheline bromide 15mg; tabs.
Roxane Laboratories, Inc.
Indications for Propantheline bromide:
Adjunctive therapy in the treatment of peptic ulcer.
15mg taken 30 minutes before each meal and 30mg at bedtime. Total daily dose: 75mg.
Glaucoma. GI obstruction (eg, pyloroduodenal stenosis, achalasia, paralytic ileus). GU obstruction (eg, bladder-neck obstruction due to prostatic hypertrophy). Intestinal atony of elderly or debilitated. Severe ulcerative colitis. Toxic megacolon. Unstable cardiovascular adjustment in acute hemorrhage. Myasthenia gravis.
High environmental temperature. Monitor for diarrhea; may be symptom of incomplete intestinal obstruction. Heart disease. CHF. Cardiac tachyarrhythmias. Hypertension. Hiatal hernia associated with reflux esophagitis. Autonomic neuropathy. Hepatic or renal disease. Hyperthyroidism. Elderly. Pregnancy (Cat.C). Nursing mothers.
Additive anticholinergic effects with concomitant belladonna alkaloids, narcotic analgesics (eg, meperidine), Class I antiarrhythmics (eg, disopyramide, procainamide, quinidine), antihistamines, phenothiazines (may potentiated sedative effects), tricyclic antidepressants, other anticholinergics. Increased intraocular pressure with concomitant corticosteroids. May potentiate slow-dissolving digoxin tablets; use rapidly-dissolving digoxin tablets instead.
Drying of salivary secretions, decreased sweating, ophthalmic effects (eg, blurred vision, mydriasis, cycloplegia, increased ocular tension), urinary hesitancy and retention, tachycardia, palpitations, loss of sense of taste, headache, nervousness, mental confusion, drowsiness, weakness, dizziness, insomnia, GI upset, constipation, bloating, impotence, lactation suppression, allergic reactions.
Formerly known under the brand name Pro-Banthine.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|